Yoshikawa R, Nakano Y, Tao L, Koishi K, Matsumoto T, Sasako M, Tsujimura T, Hashimoto-Tamaoki T, Fujiwara Y
Department of Genetics, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
Br J Cancer. 2008 May 20;98(10):1670-4. doi: 10.1038/sj.bjc.6604361. Epub 2008 May 13.
The zinc finger protein glioma-associated oncogene homologue 1 (Gli-1) is a critical component of the Hedgehog (Hh) signalling pathway, which is essential for morphogenesis and stem-cell renewal, and is dysregulated in many cancer types. As data were not available on the role of Gli-1 expression in oesophageal cancer progression, we analysed whether it could be used to predict disease progression and prognosis in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Among 69 patients with histologically confirmed oesophageal squamous cell carcinomas (ESCCs), 25 showed a pathological complete response after preoperative CRT. Overall survival (OS) was significantly associated with lymph-node metastasis, distant metastasis, and CRT, and was further correlated with the absence of both Gli-1 nuclear expression and residual tumour. All patients with Gli-1 nuclear expression (10.1%) had distant or lymph-node metastasis, and six out of seven died within 13 months. Furthermore, patients with Gli-1 nuclear-positive cancers showed significantly poorer prognoses than those without (disease-free survival: mean DFS time 250 vs 1738 months, 2-year DFS 0 vs 54.9%, P=0.009; OS: mean OS time 386 vs 1742 months, 2-year OS 16.7 vs 54.9%, P=0.001). Our study provides the first evidence that Gli-1 nuclear expression is a strong and independent predictor of early relapse and poor prognosis in ESCC after CRT. These findings suggest that Hh signal activation might promote cancer regrowth and progression after CRT.
锌指蛋白胶质瘤相关癌基因同源物1(Gli-1)是刺猬信号通路(Hh)的关键组成部分,该通路对形态发生和干细胞更新至关重要,且在多种癌症类型中失调。由于尚无关于Gli-1表达在食管癌进展中作用的数据,我们分析了它是否可用于预测接受新辅助放化疗(CRT)的食管癌患者的疾病进展和预后。在69例经组织学确诊为食管鳞状细胞癌(ESCC)的患者中,25例在术前CRT后出现病理完全缓解。总生存期(OS)与淋巴结转移、远处转移及CRT显著相关,且与Gli-1核表达缺失和无残留肿瘤进一步相关。所有Gli-1核表达阳性的患者(10.1%)均有远处或淋巴结转移,7例中有6例在13个月内死亡。此外,Gli-1核阳性癌症患者的预后明显比无核表达的患者差(无病生存期:平均DFS时间250个月对1738个月,2年DFS率0%对54.9%,P=0.009;OS:平均OS时间386个月对1742个月,2年OS率16.7%对54.9%,P=0.001)。我们的研究首次证明,Gli-1核表达是CRT后ESCC早期复发和预后不良的有力且独立的预测指标。这些发现提示,Hh信号激活可能促进CRT后癌症的再生长和进展。